Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;32(6):1414-1420.
doi: 10.1038/s41375-018-0099-8. Epub 2018 Mar 21.

Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset

Gaurav Goyal  1 , Adam C Bartley  2 , Shealeigh Funni  3 , Jonathan Inselman  3 , Nilay D Shah  3 , Ariela L Marshall  4 , Aneel A Ashrani  4 , Prashant Kapoor  4 , Urshila Durani  4 , Shahrukh K Hashmi  4 , Mustaqeem A Siddiqui  4 , Francis K Buadi  4 , Ronald S Go  4 , Robert A Kyle  4 , Shaji Kumar  4 , Wilson I Gonsalves  4
Affiliations

Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset

Gaurav Goyal et al. Leukemia. 2018 Jun.

Abstract

Solitary plasmacytomas are uncommon plasma cell disorders, which may present as a single bone lesion (P-bone) or extramedullary plasmacytoma (P-EM). There is a paucity of large studies analyzing prognostic factors and outcomes of plasmacytomas. While the treatment of choice is radiation therapy (RT), there is a lack of data evaluating optimal RT dose. In this study, we sought to answer these questions by utilizing the National Cancer Database plasmacytoma data from 2000 to 2011. A total of 5056 patients were included in the study (median age 62 years; range 52-72). To obtain a pure plasmacytoma cohort, potential multiple myeloma patients were excluded from the study (bone marrow involvement, systemic chemotherapy use). P-bone constituted 70% of the patients. The median overall survival (OS) of P-EM was significantly longer than P-bone (132 vs. 85 months), and for soft/connective tissue it was worse than remainder of P-EM (82 vs. 148 months). On multivariable analysis, factors associated with worse OS included older age (≥65), presence of P-bone, and treatment with a radiation dose <40 Gy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CONSORT diagram for cohort selection.
Figure 2.
Figure 2.
Overall survival (OS) based on location of plasmacytoma (A) Extramedullary plasmacytoma (P-EM) compared to bone plasmacytoma; (B) Plasmacytoma of soft/connective tissue compared to others (P-EM other than connective/soft tissue or P-bone).
Figure 3.
Figure 3.
Regression tree for upper aero-digestive tract site subgroup analysis of radiation dose.
See this image and copyright information in PMC

References

    1. Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992–2004. Br J Haematol 2009. January; 144(1): 86–94. - PMC - PubMed
    1. Thumallapally N, Meshref A, Mousa M, Terjanian T. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer 2017. January 05; 17(1): 13. - PMC - PubMed
    1. Holland J, Trenkner DA, Wasserman TH, Fineberg B. Plasmacytoma. Treatment results and conversion to myeloma. Cancer 1992. March 15; 69(6): 1513–1517. - PubMed
    1. Knobel D, Zouhair A, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer 2006; 6: 118. - PMC - PubMed
    1. Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1983. April; 1(4): 255–262. - PubMed

Publication types